Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke

International Journal of Neuroscience

Volumn 126, Issue 8, 2016, Pages 675-680

  Zhang, Lingling ^a   Song, Kangping ^a   Zhu, Mengting ^a   Shi, Jinling ^a   Zhang, Huijuan ^a   Xu, Liang ^a   Chen, Yingzhu ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

atherosclerosis; ischemic stroke; LDL C; LDLR; lipid metabolism; PCSK9

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CORRELATION ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LIPID METABOLISM; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; HYPERCHOLESTEROLEMIA; METABOLISM; PHYSIOLOGY; STROKE;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9; STROKE;

EID: 84978760213     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1057636     Document Type: Review

References (52)

1. N.G.Seidah, S.Benjannet, L.Wickham, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci US 2003;100:928–33.
2. Y.G.Saavedra, J.Zhang, N.G.Seidah. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation. PloS One 2013;8:e72113.
3. J.Mayne, T.C.Ooi, A.Raymond, Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Disease 2013;12:70.
4. G.D.Norata, K.Garlaschelli, L.Grigore, Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177–82.
5. Y.Q.Chen, J.S.Troutt, R.J.Konrad. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids 2014;49:445–55.
6. C.J.Lee, Y.H.Lee, S.W.Park, Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism 2013;62:845–50.
7. A.Slimani, Y.Harira, I.Trabelsi, Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort. J Mol Neurosci 2014;53:150–7.
8. S.Li, Y.L.Guo, R.X.Xu, Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiology 2014;174:863–4.
9. S.Abboud, P.J.Karhunen, D.Lutjohann, Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PloS One 2007;2:e1043.
10. M.Farnier. PCSK9: From discovery to therapeutic applications. Arch Cardiovascular Diseases 2014;107:58–66.
11. N.G.Seidah, A.Prat. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discovery 2012;11:367–83.
12. S.Benjannet, Y.G.Saavedra, J.Hamelin, Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem 2010;285:40965–78.
13. D.W.Zhang, R.Garuti, W.J.Tang, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 2008;105:13045–50.
14. P.Lo Surdo, M.J.Bottomley, A.Calzetta, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011;12:1300–5.
15. M.C.McNutt, H.J.Kwon, C.Chen, Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009;284:10561–70.
16. K.M.Timms, S.Wagner, M.E.Samuels, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genetics 2004;114:349–53.
17. D.Cunningham, D.E.Danley, K.F.Geoghegan, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14:413–9.
18. M.Abifadel, M.Guerin, S.Benjannet, Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012;223:394–400.
19. Z.Zhao, Y.Tuakli, T.A.Lagace, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genetics 2006;79:514–23.
20. A.Slimani, A.Jelassi, I.Jguirim, Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis 2012;222:158–66.
21. T.Fasano, X.M.Sun, D.D.Patel, Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells. Atherosclerosis 2009;203:166–71.
22. A.L.Catapano, N.Papadopoulos. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228:18–28.
23. S.Poirier, G.Mayer. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Dev Ther 2013;7:1135–48.
24. J.M.Anderson, A.Cerda, M.H.Hirata, Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. J Clin Lipidology 2014;8:256–64.
25. S.Poirier, G.Mayer, S.Benjannet, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283:2363–72.
26. S.Benjannet, D.Rhainds, R.Essalmani, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279:48865–75.
27. A.Roubtsova, M.N.Munkonda, Z.Awan, Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arteriosclerosis Thrombosis Vascular Biol 2011;31:785–91.
28. S.Choi, A.Aljakna, U.Srivastava, Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Disease 2013;12:112.
29. J.Sanz, P.R.Moreno, V.Fuster. The year in atherothrombosis. J Am Coll. Cardiology 2013;62:1131–43.
30. P.Libby, A.H.Lichtman, G.K.Hansson. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013;38:1092–104.
31. M.C.Cure, A.Tufekci, E.Cure, Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. Ann Indian Acad Neurology 2013;16:498–503.
32. F.Cipollone, L.Felicioni, R.Sarzani, A unique microRNA signature associated with plaque instability in humans. Stroke 2011;42:2556–63.
33. G.W.Stone, A.Maehara, A.J.Lansky, A prospective natural-history study of coronary atherosclerosis. New England J Med 2011;364:226–35.
34. T.C.Nichols. Bad cholesterol breaking really bad. Blood 2013;122:3551–3.
35. M.Denis, J.Marcinkiewicz, A.Zaid, Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012;125:894–901.
36. N.Ferri, G.Tibolla, A.Pirillo, Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012;220:381–6.
37. K.L.Furie, S.E.Kasner, R.J.Adams, Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227–76.
38. N.G.Seidah. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Therapeutic Targets 2009;13:19–28.
39. D.Urban, J.Poss, M.Bohm, Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll. Cardiology 2013;62:1401–8.
40. Z.Tang, L.Jiang, J.Peng, PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med 2012;30:931–8.
41. C.Y.Wu, Z.H.Tang, L.Jiang, PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 2012;359:347–58.
42. M.Mbikay, F.Sirois, J.Mayne, PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010;584:701–6.
43. V.Sharotri, D.M.Collier, D.R.Olson, Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem 2012;287:19266–74.
44. C.F.Tsai, B.Thomas, C.L.Sudlow. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013;81:264–72.
45. G.J.Hankey. Secondary stroke prevention. Lancet Neurology 2014;13:178–94.
46. N.W.Tsai, L.H.Lee, C.R.Huang, Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care 2014;18:R16.
47. Y.Huang, D.G.Ballinger, R.Stokowski, Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med 2012;4:57.
48. S.Ebrahim, J.Sung, Y.M.Song, Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006;333:22.
49. G.Saposnik, G.C.Fonarow, W.Pan, Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from get with the guidelines-stroke 2003 to 2012. Stroke 2014;45:3343–51.
50. D.Han, J.Ma, X.Zhang, Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations. Med Sci Monitor 2014;20:1758–67.
51. H.M.Colhoun, J.G.Robinson, M.Farnier, Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders 2014;14:121.
52. D.A.Marais, D.J.Blom, F.Petrides, Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidology 2012;23:511–7.